Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone

Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone

Written by Customer Service on . Posted in Public Companies.

DANBURY, Conn., June 11, 2023 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12. The visit coincides with MannKind reaching a manufacturing milestone as it has successfully scaled-up operations for increased production capacity of Tyvaso DPI®.

Through MannKind’s partnership with United Therapeutics the current expansion project represents a $60 million investment. Construction is ongoing to build out new manufacturing space designed to expand production in anticipation of the continued growth of Tyvaso DPI. In the past two years, MannKind has experienced more than a 250% increase in its Connecticut workforce across manufacturing, R&D and support functions.

DATE/TIMES: MONDAY, JUNE 12, 2023
  10:00 a.m. – 11:00 a.m.
   
LOCATION:  MannKind
  40 Taylor Street (Danbury, CT)
   
VISUALS/SOUND: – Governor Lamont tours facility with MannKind CEO Dr. Michael Castagna and COO Lauren Sabella
  – Construction underway on “clean rooms” and spray dry equipment in new manufacturing space
  – Demonstration of MannKind’s innovative Technosphere® particle and device technologies
  – Production personnel producing the particle technology used as part of our inhaled insulin (Afrezza®) as well as Tyvaso DPI
   
MANNKIND: MannKind Corporation focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.

CONTACT:  MannKind Corporate Communications
  Christie Iacangelo (on-site)   
  (818) 292-3500 (mobile)
  ciacangelo@mnkd.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.